Risk Stratified Imputation in Informative Censoring

Size: px
Start display at page:

Download "Risk Stratified Imputation in Informative Censoring"

Transcription

1 Risk Stratified Imputation in Informative Censoring Richard E. Kennedy, 1 Kofi fip. Adragni, 2 Hemant K. Tiwari, 1 Jenifer H. Voeks, 3 Thomas G. Brott, 4 and George Howard 1 1 Department of Biostatistics University of Alabama at Birmingham Birmingham AL 1 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 2 Department of Statistics and Actuarial Science, University of Iowa, Iowa City, IA 3 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 4 Department of Neurology, Mayo Clinic, Jacksonville, FL

2 Motivating Study Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) 2502 patients randomized to traditional surgery (endarterectomy CEA) versus novel endovascular (carotid stenting CAS) therapy Pi Primary outcome Stroke, MI or death in periprocedural period Ipsilateral stroke afterward

3 How the best of intentions can get you into quite a pickle Much higher withdrawal rates in CAS than CEA Randomization could be on the basis of ultrasound Subsequent angiography in CAS group only could show patient ineligible for treatment Powerful predictors of ineligibility included age and disease severity (both tightly tied to outcomes) Untreated were more likely to withdraw from follow up Approximately half way through recruitment, policy was instituted where coordinators had to call study PI to discuss each case of dropout Dramatic decline in dropouts

4 How the best of intentions can get you into quite a pickle Also large changes in eligibility over time Eligibility was originally only symptomatic patients Approximately half way through enrollment, opened to asymptomatic patients Asymptomatic patients are at much lower risk of events Hence, no real reason to think randomization ato balanced risk in the study groups High dropout of high risk patients only in CAS group early Inclusion of low risk patients (asymptomatics) relatively l uniform later need to institute some kind ofadjustment to more truly implement intention to treat

5 Imputation Aims Focus needed dto be on treatment dff difference in withdrawals Procedures arewell known, as arepredictors of outcome events (age, symptomatic status, degree of stenosis, and gender) Primary analysis plan included covariate adjustment However, withdrawals require secondary analysis accounting for missing data Withdrawals da asaebas are basically only missing data a and a target for multiple imputation Situation where withdrawals (missing data) are associated itdwith both covariates it and likelihood lih of study outcomes

6 Approach of Taylor Failure Withdrawn Censored Original sample Taylor JMG. Statistics & Probability Letters 2002; 58:

7 Approach of Taylor Failure Withdrawn Censored Original sample Create m bootstrap samples of size n Taylor JMG. Statistics & Probability Letters 2002; 58:

8 Approach of Taylor Failure Withdrawn Censored Original sample Create m bootstrap samples of size n Impute withdrawals and censored from those remaining in the study at the time of removal for the index case Taylor JMG. Statistics & Probability Letters 2002; 58:

9 Approach of Taylor Failure Withdrawn Censored Original sample Create m bootstrap samples of size n Impute withdrawals and censored from those remaining in the study at the time of removal for the index case Analyze using Rubin and Little Taylor JMG. Statistics & Probability Letters 2002; 58:

10 Proposed Risk Stratification Approach Failure Withdrawn Censored Original sample

11 Proposed Risk Stratification Approach Failure Withdrawn Censored Original sample Risk stratify by by covariate

12 Proposed Risk Stratification Approach Failure Withdrawn Censored Original sample Risk stratify by by covariate Impute m datasets withdrawal using failures or those reaching end of study

13 Proposed Risk Stratification Approach Failure Withdrawn Censored Original sample Risk stratify by by covariate Impute m datasets withdrawal using failures or those reaching end of study Combine back into m datasets

14 Proposed Risk Stratification Approach Failure Withdrawn Censored Risk stratify by by covariate Impute m datasets withdrawal using failures or those reaching end of study Combine back into m datasets Analyze using Rubin and Little

15 Simulation Design Considered one factor of interest (treatment) and one covariate (measure of risk) Considered 5 scenarios Treatment/covariate related to The neither scenario outcome nor withdrawals that we thin Treatment related to outcome only CREST has Treatment related to outcome and withdrawal Treatment related to outcome and withdrawal, covariate related to outcome only Treatment and covariate related to both outcome and withdrawal Performance was evaluated by root mean square error (magnitude of bias) and proportional coverage ofknown parameter

16 Simulation Outcomes Scenario 1 failure: 19% Treatment/covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment related to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 fil failure: 16% Treatment and covariate related to withdraw: 18% both outcome and withdrawal censored: 66% Complete Data Risk Stratified Imputation ( ) Bootstrap Imputation (Taylor) ( ) Mean (SE) ( ) 00010) ( ) ( ) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) (0.0011) (0.0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

17 Simulation Outcomes Scenario 1 failure: 19% Treatment/covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment related to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 failure: 16% Treatment and covariate related to withdraw: 18% both outcome and wiithdrawal censored: 66% Complete Data Risk Stratified Imputation ( ) Bootstrap Imputation (Taylor) ( ) Mean (SE) ( ) 00010) ( ) ( ) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) 0011) (0.0011) 0011) (0.0011) 0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

18 Simulation Outcomes Scenario 1 failure: 19% Treatment/covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment related to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 failure: 16% Treatment and covariate related to withdraw: 18% both outcome and withdrawal censored: 66% Complete Data Risk Stratified Imputation ( ) Bootstrap Imputation (Taylor) ( ) Mean (SE) ( ) 00010) ( ) ( ) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) 0011) (0.0011) 0011) (0.0011) 0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

19 Simulation Outcomes Scenario 1 failure: 19% Treatment/covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment related to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 failure: 16% Treatment and covariate related to withdraw: 18% both outcome and withdrawal censored: 66% Complete Data Risk Stratified Imputation ( ) Bootstrap Imputation (Taylor) ( ) Mean (SE) ( ) 00010) ( ) ( ) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) 0011) (0.0011) 0011) (0.0011) 0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

20 Simulation Outcomes Scenario 1 failure: 19% Treatment/covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment related to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 fil failure: 16% Treatment and covariate related to withdraw: 18% both outcome and withdrawal censored: 66% Risk Bootstrap Complete Stratified Imputation Data Imputation (Taylor) Mean (SE) ( ) 00010) ( ) 00010) ( ) 00010) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) (0.0011) (0.0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

21 Simulation Outcomes Scenario 1 failure: aue: 19% Treatment/Covariate related to withdraw: 7% neither outcome or withdrawals censored: 75% Scenario 2 Treatment realted to outcome only failure: 13% withdraw: 7 % censored: 80% Scenario 3 failure: 17% Treatment related to outcome and withdraw: 7% withdrawal censored: 76% Scenario 4 Treatment related to outcome and withdrawal, covariate related to outcome only failure: 16% withdraw: 13% censored: 71% Scenario 5 fil failure: 16% Treatment and covariate related to withdraw: 18% both outcome and wihedrawal censored: 66% Risk Bootstrap Complete Stratified Imputation Data Imputation (Taylor) Mean (SE) ( ) 00010) ( ) 00010) ( ) 00010) RMSE Coverage Mean (SE) RMSE Coverage Mean (SE) (0.0011) (0.0011) (0.0011) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage Mean (SE) ( ) ( ) ( ) RMSE Coverage

22 Conclusions Approach appears to address the difficult issue when treatment t tand patient t characteristics ti are related to both outcomes and withdrawal Easy to implement Secondary analysis in CREST proved to be quite similar to primary analysis (after all this in this study it did not matter!!!) Better safe than sorry!

23 Thanks to the CREST co authors, Investigators, and patients!

Update : Carotid Stenting and Current Trial Data

Update : Carotid Stenting and Current Trial Data Update : Carotid Stenting and Current Trial Data J. Michael Bacharach, MD, MPH, FACC, FSCAI Section Head, Vascular Medicine and Vascular Intervention North Central Heart Institute, Sioux Falls, South Dakota

More information

Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective)

Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective) Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective) T-Woei Tan, MD, FACS, RPVI Assistant Professor of Surgery Vascular and Endovascular Surgery Louisiana State University Health -

More information

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2 Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety

More information

How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention

How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention Christopher J. White MD, MSCAI Chief of Medical Services, Professor and Chairman of Medicine Ochsner Medical Center

More information

CLINICAL TIMELINE EVA-3S CREST ICSS SPACE SAPPHIRE

CLINICAL TIMELINE EVA-3S CREST ICSS SPACE SAPPHIRE Normal Risk Symptomatic Patients: Ongoing Debate CAS vs CEA John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center University of California, Davis CLINICAL TIMELINE Randomized

More information

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic State of the Art Management of Carotid Stenosis Mark R. Harrigan, MD UAB Stroke Center Professor of Neurosurgery, Neurology, and Radiology University of Alabama, Birmingham Disclosures NIH funding for

More information

Stroke prevention in asymptomatic carotid stenosis. ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ

Stroke prevention in asymptomatic carotid stenosis. ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ Stroke prevention in asymptomatic carotid stenosis ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ Σεμινάρια Ομάδων Εργασίας Ελληνικής Καρδιολογικής Εταιρείας

More information

CAROTID ARTERY ANGIOPLASTY

CAROTID ARTERY ANGIOPLASTY CAROTID ARTERY ANGIOPLASTY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome Measure #344: Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Effective Clinical

More information

The Great Swedish Debate. Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund

The Great Swedish Debate. Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund The Great Swedish Debate Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund My Disclosures Trying to bribe the moderators What do my patients expect? Balanced information

More information

Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine

Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Institute The Oregon Clinic Disclosure I declare that neither

More information

Contemporary Management of Carotid Disease What We Know So Far

Contemporary Management of Carotid Disease What We Know So Far Contemporary Management of Carotid Disease What We Know So Far Ammar Safar, MD, FSCAI, FACC, FACP, RPVI Interventional Cardiology & Endovascular Medicine Disclosers NONE Epidemiology 80 % of stroke are

More information

Carotid Artery Stenosis

Carotid Artery Stenosis Evidence-Based Approach to Carotid Artery Stenosis Seong-Wook Park, MD Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Carotid Artery Stenosis Carotid

More information

For the ICSS Investigators. 7 th Munich Vascular Conference Munich, 7 December 2017

For the ICSS Investigators. 7 th Munich Vascular Conference Munich, 7 December 2017 Restenosis and its impact on recurrent stroke risks after CAS and CEA for symptomatic carotid stenosis results from the International Carotid Stenting Study Leo H Bonati, John Gregson, Joanna Dobson, Dominick

More information

Carotid Artery Stenting Versus

Carotid Artery Stenting Versus Carotid Artery Stenting Versus Carotid Endarterectomy Seong-Wook Park, MD, PhD, FACC,, Seoul, Korea Stroke & Carotid artery stenosis Stroke & Carotid artery stenosis Cerebrovascular disease is one of the

More information

Internal carotid artery near-total occlusions: Is it justified to operate on them?

Internal carotid artery near-total occlusions: Is it justified to operate on them? Internal carotid artery near-total occlusions: Is it justified to operate on them? Christos D. Liapis Professor (Em) of Vascular Surgery Athens University Medical School Director Vascular & Endovascular

More information

Surgical Treatment of Carotid Disease

Surgical Treatment of Carotid Disease Department of Cardiothoracic & Vascular Surgery McGovern Medical School / The University of Texas Health Science Center at Houston Surgical Treatment of Carotid Disease The Old, the New, and the Future

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome Quality ID #345 (NQF 1543): Rate of Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) Who Are Stroke Free or Discharged Alive National Quality Strategy Domain: Effective Clinical Care 2018

More information

TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS

TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS Assistant Professor of Surgery Director of Carotid Interventions Division of Vascular & Endovascular Surgery Stony Brook University

More information

Will guidelines and clinical practice for asymptomatic stenosis change in the near future?

Will guidelines and clinical practice for asymptomatic stenosis change in the near future? Will guidelines and clinical practice for asymptomatic stenosis change in the near future? M Storck, MD, PhD Director Dept. Vascular and Thoracic Surgery Klinikum Karlsruhe Academic Teaching Hospital,

More information

Carotid Stenosis 1/24/2019. Review of Primary Studies. NASCET- Moderate stenosis. ACAS (Asymptomatic Carotid Atherosclerosis Study) NASCET

Carotid Stenosis 1/24/2019. Review of Primary Studies. NASCET- Moderate stenosis. ACAS (Asymptomatic Carotid Atherosclerosis Study) NASCET Review of Primary Studies Carotid Stenosis NINDS National Institute of Neurological Disorders and Stroke 2 large studies to determine who would benefit from surgery NASCET North American Symptomatic Carotid

More information

CAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital

CAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital CAROTID STENTING A 2009 UPDATE Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital TREATMENT FOR CAROTID STENOSIS Best medical management Antiplatelet therapy Antihypertensive

More information

AN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS

AN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS Pak Heart J ORIGINAL ARTICLE AN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS 1 2 3 4 5 Abhishek Nemani, Arshad Ali, Arshad Rehan, Ali Aboufaris, Jabar Ali 1-4 Guthrie

More information

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery Treatment Considerations for Carotid Artery Stenosis Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery 4.29.2016 There is no actual or potential conflict of interest in regards to this presentation

More information

Latest Advances in the Neurointerventional Treatment of Ischemic Stroke P A C I F I C N E U R O. O R G

Latest Advances in the Neurointerventional Treatment of Ischemic Stroke P A C I F I C N E U R O. O R G Latest Advances in the Neurointerventional Treatment of Ischemic Stroke Neurointerventional Management of Ischemic Stroke 1. Thrombectomy for acute ischemic stroke 2. Carotid artery stenting 3. Management

More information

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,

More information

The argument against revascularization for asymptomatic carotid stenosis

The argument against revascularization for asymptomatic carotid stenosis The argument against revascularization for asymptomatic carotid stenosis Seemant Chaturvedi, MD, FAHA, FAAN Professor of Clinical Neurology Vice-Chair for VA Programs Univ. of Miami Miller School of Medicine

More information

BULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial

BULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial BULgarian Carotid Artery Stenting versus Surgery Study (): Randomized single center trial Ivo Petrov, M. Konteva, H. Dimitrov, K. Kichukov Tokuda Hospital Sofia Cardiology Department Background Carotid

More information

Carotid Artery Stenting

Carotid Artery Stenting Carotid Artery Stenting Woong Chol Kang M.D. Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Carotid Stenosis and Stroke ~25% of stroke is due to carotid disease, the reminder

More information

Carotid. The. Issue. Now approved by the FDA, carotid stenting moves into the spotlight in endovascular care.

Carotid. The. Issue. Now approved by the FDA, carotid stenting moves into the spotlight in endovascular care. The Carotid Issue 33 Carotid Revascularization in 2004 By Thomas G. Brott, MD; Jamie Roberts, LPN, CRC; Robert W. Hobson II, MD; and Susan Hughes, BSN Now approved by the FDA, carotid stenting moves into

More information

Asymptomatic Carotid Stenosis To Do or Not To Do

Asymptomatic Carotid Stenosis To Do or Not To Do Asymptomatic Carotid Stenosis To Do or Not To Do October 22, 2016 Neurosciences: Updates and Controversies Andrew C. MacDougall, MD Advocate Medical Group Advocate Lutheran General Hospital Principle

More information

The most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease

The most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease The most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease GJ de Borst Department of Vascular Surgery RECOMMENDATION GRADING CRITERIA What is new

More information

The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered?

The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered? TCT 2009 San Francisco, California September 22, 2009 The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered? Michael

More information

Alma Mater Studiorum Università di Bologna

Alma Mater Studiorum Università di Bologna Alma Mater Studiorum Università di Bologna S.Orsola-Malpighi, Bologna, Italia Chirurgia Vascolare The volume of cerebral ischaemic lesion predicts the outcome after symptomatic carotid revascularisation

More information

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai CardioLucca2014 Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee Fabrizio Tomai European Hospital e Aurelia Hospital Roma Treatment of Carotid Artery Disease

More information

Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion

Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion Paul Hsien-Li Kao, MD Assistant Professor National Taiwan University Medical School and Hospital ICA stenting

More information

Carotid stenosis management: CAS or CEA? Yaoguo Yang, Chen Zhong Beijing Anzhen Hospital,China

Carotid stenosis management: CAS or CEA? Yaoguo Yang, Chen Zhong Beijing Anzhen Hospital,China Carotid stenosis management: CAS or CEA? Yaoguo Yang, Chen Zhong Beijing Anzhen Hospital,China Disclosure Speaker name:... I have the following potential conflicts of interest to report: Consulting Employment

More information

Carotid Artery Stenting Today: A Few Updating Remarks

Carotid Artery Stenting Today: A Few Updating Remarks Carotid Artery Stenting Today: A Few Updating Remarks Camilo R. Gomez, MD, MBA Director, Alabama Neurological Institute Birmingham, Alabama Disclaimer & Warning Company Pharmaceutical BMS-Sanofi-Aventis

More information

a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers

a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers The study a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers Conflict of interest have the following potential conflicts of interest to report: Consulting

More information

Clinical experience amongst surgeons in the Asymptomatic Carotid Surgery Trial-1 (ACST-1)

Clinical experience amongst surgeons in the Asymptomatic Carotid Surgery Trial-1 (ACST-1) Clinical experience amongst surgeons in the Asymptomatic Carotid Surgery Trial-1 (ACST-1) Short Title: Clinical experience in the Asymptomatic Carotid Surgery Trial-1 (ACST-1) Authors: Anne Huibers 1,2,

More information

Carotid Disease and CABG: What is the best Treatment

Carotid Disease and CABG: What is the best Treatment Carotid Disease and CABG: What is the best Treatment Dual Antiplatelets Luis A Guzman, MD, FACC, FSCAI Professor of Medicine Director, Cardiovascular Cath Lab Virginia Commonwealth University Stroke during

More information

SCAFFOLD Study Gore PTFE mesh-covered stent preclinical and clinical data so far. Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii

SCAFFOLD Study Gore PTFE mesh-covered stent preclinical and clinical data so far. Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii SCAFFOLD Study Gore PTFE mesh-covered stent preclinical and clinical data so far Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have the following

More information

Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis

Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis Original Article Long-Term Results of versus for Carotid-Artery Stenosis Thomas G. Brott, M.D., George Howard, Dr.P.H., Gary S. Roubin, M.D., Ph.D., James F. Meschia, M.D., Ariane Mackey, M.D., William

More information

Lecture Outline: 1/5/14

Lecture Outline: 1/5/14 John P. Karis, MD Lecture Outline: Provide a clinical overview of stroke: Risk Prevention Diagnosis Intervention Illustrate how MRI is used in the diagnosis and management of stroke. Illustrate how competing

More information

The Carotid Revascularization Endarterectomy vs. Stenting Trial completes randomization: Lessons learned and anticipated results

The Carotid Revascularization Endarterectomy vs. Stenting Trial completes randomization: Lessons learned and anticipated results Thomas L. Forbes, MD, Section Editor CLINICAL TRIALS UPDATE The Carotid Revascularization Endarterectomy vs. Stenting Trial completes randomization: Lessons learned and anticipated results Brajesh K. Lal,

More information

I have the following potential conflicts of interest to report. honorarium: 1. St Jude Medical 2. Biotronik 3. Boston Scientific

I have the following potential conflicts of interest to report. honorarium: 1. St Jude Medical 2. Biotronik 3. Boston Scientific Stenting carotideo nel paziente sintomatico alla luce dei nuovi trials Savona, 11 Aprile 2015 Gioel GabrioSecco, MD, PhD Emodinamica e CardiologiaInterventistica Ospedale SantiAntonio e Biagio e Cesare

More information

Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS. Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford

Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS. Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford Two BIG questions in carotid research Question #1 Should we

More information

TITLE: Carotid Artery Stenting versus Carotid Endarterectomy: A Review of the Clinical and Cost-Effectiveness

TITLE: Carotid Artery Stenting versus Carotid Endarterectomy: A Review of the Clinical and Cost-Effectiveness TITLE: Carotid Artery Stenting versus Carotid Endarterectomy: A Review of the Clinical and Cost-Effectiveness DATE: 22 September 2009 CONTEXT AND POLICY ISSUES: A stroke is an interruption of blood supply

More information

CAROTID ARTERY ANGIOPLASTY

CAROTID ARTERY ANGIOPLASTY CAROTID ARTERY ANGIOPLASTY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and

More information

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic

More information

Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii

Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have the following potential conflicts of

More information

Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC

Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC GVM Care & Research - Cardiovascular Department (Cotignola Italy) Hypothesis: Does CAS present similar outcomes than

More information

Neurosurgical decision making in structural lesions causing stroke. Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery)

Neurosurgical decision making in structural lesions causing stroke. Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery) Neurosurgical decision making in structural lesions causing stroke Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery) Subarachnoid Hemorrhage Every year, an estimated 30,000 people in the United States experience

More information

Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO

Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Goal of treatment of carotid disease Identify those at risk of developing symptoms Prevent patients at risk from developing symptoms Prevent

More information

Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk

Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk Amy B. Reed, MD, a Peter Gaccione, MA, b Michael Belkin, MD, b Magruder C. Donaldson, MD, b John A. Mannick, MD,

More information

Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2

Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2 Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2 Alison Halliday MD Professor of Vascular Surgery University of Oxford Disclosure Statement of Financial

More information

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE? UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE? Richard W. Petrella M.D. FACP,FACC,FASCI DEPARTMENT CHAIRMAN CVM&S UPMC HAMOT MEDICAL CENTER 1 LEARNING OBJECTIVES REVIEW THE RISK FACTORS FOR

More information

ACE Standards. for Carotid Artery Stenting Accreditation. Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care

ACE Standards. for Carotid Artery Stenting Accreditation. Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care 2010 ACE Standards for Carotid Artery Stenting Accreditation Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care 2400 N Street NW, Suite 500 Washington, D.C. 20037-1153

More information

DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC LEIPZIG JANUARY 27, 2015

DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC LEIPZIG JANUARY 27, 2015 DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC - 2015 LEIPZIG JANUARY 27, 2015 Disclosure Speaker name: FRANK J. VEITH DESPITE SOME

More information

Carotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA

Carotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA Carotid Artery Stenting (CAS) Carotid Artery Stenting for Stroke Risk Reduction Matthew A. Corriere MD, MS, RPVI Assistant Professor of Surgery Department of Vascular and Endovascular Surgery Rationale:

More information

Phase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine

Phase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine Phase III Clinical Trial Randomization, Blinding and Baseline Assessment Chi-hong Tseng, PhD Statistics Core, Department of Medicine Reference Clinical Trials: A Practical Approach. Pocock SJ. Wiley, Chichester,

More information

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no

More information

SAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D

SAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D SAMMPRIS Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis Khalil Zahra, M.D Major points Patients with recent TIA or stroke and intra-cranial artery

More information

Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials

Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies

More information

My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position

My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position LINC 2016 Leipzig, Jan 26-29, 2016 My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position Horst Sievert, Iris Grunwald CardioVasculäres Centrum Frankfurt - CVC, Frankfurt

More information

LARGE ARTERY DISEASE pathophysiology of ischemic insults. ISCHEMIC STROKE & TIA main etiologies

LARGE ARTERY DISEASE pathophysiology of ischemic insults. ISCHEMIC STROKE & TIA main etiologies תאריך בדיקה- 27.1.04 דופלקס עורקי צוואר - משמעות בגיל הקשיש דר' יונתן שטרייפלר מנהל היחידה הנוירולוגית מרכז רפואי רבין - בי"ח השרון ISCHEMIC STROKE & TIA main etiologies Large vessel (artery) disease -

More information

Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: Executive summary

Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: Executive summary SOCIETY FOR VASCULAR SURGERY DOCUMENT Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: Executive summary John J. Ricotta, MD, a Ali AbuRahma, MD, FACS, b

More information

Epidemiology/Biostatistics Working Group

Epidemiology/Biostatistics Working Group Epidemiology/Biostatistics Working Group CCSS PI Meeting June 6-7, 2012 WG Committee Priorities Opportunity to publish methodology publications Evaluate and respond to methodological issues that arise

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and

More information

ISCHEMIC STROKE & TIA main etiologies

ISCHEMIC STROKE & TIA main etiologies דופלקס עורקי צוואר - משמעות בגיל הקשיש דר' יונתן שטרייפלר מנהל היחידה הנוירולוגית מרכז רפואי רבין - בי"ח השרון תאריך בדיקה- 27.1.04 ISCHEMIC STROKE & TIA main etiologies Large vessel (artery) disease -

More information

Extracranial Carotid Artery/Stenting

Extracranial Carotid Artery/Stenting Extracranial Carotid Artery/Stenting Policy Number: 7.01.68 Last Review: 6/2017 Origination: 4/2005 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough

CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough Todd W GenslerMD April 28, 2018 CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough DISCLOSURES I have no financial disclosures Presenter name

More information

Carotid Artery Stent: Is it ready for prime time?

Carotid Artery Stent: Is it ready for prime time? 2010 CATH LAB SYMPOSIUM Carotid Artery Stent: Is it ready for prime time? Luis F. Tami, MD, FACC, FSCAI Interventional Cardiology and Vascular Medicine Memorial Regional Hospital August 2010 CAE and CAS

More information

Carotid Stenting and Surgery in 2016 in Russia

Carotid Stenting and Surgery in 2016 in Russia Carotid Stenting and Surgery in 2016 in Russia Novosibirsk research institute of circulation pathology named by Meshalkin, Novosibirsk, Russia Starodubtsev V., Karpenko A., Ignatenko P. Annually in Russia

More information

How Duplex Ultrasound Screening Can Lead to Overuse of Carotid Interventions. No Disclosures. Prevalence >70% Asymptomatic ICA Stenosis*

How Duplex Ultrasound Screening Can Lead to Overuse of Carotid Interventions. No Disclosures. Prevalence >70% Asymptomatic ICA Stenosis* How Duplex Ultrasound Screening Can Lead to Overuse of Carotid Interventions Gregory L. Moneta, M.D. Chief, Division of Vascular Surgery Department of Surgery Knight Cardiovascular Institute Oregon Health

More information

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Carotid Artery Revascularization: Current Strategies Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Disclosures None 1 Stroke in 2014 Stroke kills almost

More information

Analyzing diastolic and systolic blood pressure individually or jointly?

Analyzing diastolic and systolic blood pressure individually or jointly? Analyzing diastolic and systolic blood pressure individually or jointly? Chenglin Ye a, Gary Foster a, Lisa Dolovich b, Lehana Thabane a,c a. Department of Clinical Epidemiology and Biostatistics, McMaster

More information

Emboli detection to evaluate risk of stroke

Emboli detection to evaluate risk of stroke Emboli detection to evaluate risk of stroke Background: Improved methods are required to identify patients with asymptomatic carotid stenosis at high risk for stroke. Whether surgery is beneficial for

More information

Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods

Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods Merrill and McClure Trials (2015) 16:523 DOI 1186/s13063-015-1044-z TRIALS RESEARCH Open Access Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of

More information

Articles. Funding Medical Research Council, the Stroke Association, Sanofi-Synthélabo, European Union.

Articles. Funding Medical Research Council, the Stroke Association, Sanofi-Synthélabo, European Union. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial International

More information

Carotid Revascularization

Carotid Revascularization Options for Carotid Disease Carotid Revascularization Wayne Causey, MD 2 nd Year Vascular Surgery Fellow Best medical therapy, Carotid Endarterectomy, and Carotid Stenting Who benefits from best medical

More information

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008 New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants

More information

Credentialing of surgeons as interventionalists for carotid artery stenting: Experience from the leadin phase of CREST

Credentialing of surgeons as interventionalists for carotid artery stenting: Experience from the leadin phase of CREST From the Society for Vascular Surgery Credentialing of surgeons as interventionalists for carotid artery stenting: Experience from the leadin phase of CREST Robert W. Hobson II, MD, a Virginia J. Howard,

More information

Disclosures. CREST Trial: Summary. Lecture Outline 4/16/2015. Cervical Atherosclerotic Disease

Disclosures. CREST Trial: Summary. Lecture Outline 4/16/2015. Cervical Atherosclerotic Disease Disclosures Your Patient Has Carotid Bulb Stenosis and a Tandem Intracranial Stenosis: How Do SAMMPRIS and Other Evidence Inform Your Treatment? UCSF Vascular Symposium 2015 Steven W. Hetts, MD Associate

More information

Carotid artery stents and embolic protection

Carotid artery stents and embolic protection Regulation of Carotid Artery Stents and Embolic Protection Devices in the United States A history of, and perspectives on, FDA regulation of carotid stents and associated embolic protection devices over

More information

MEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany

MEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany MEET Θ 2006 Why I stent asymptomatic and symptomatic patients K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany Evidence for treating symptomatic patients symptomatic patients

More information

initial DUS imaging followed by contrast-enhanced magnetic resonance angiography (CEMRA) when DUS demonstrates 50% or higher stenosis;

initial DUS imaging followed by contrast-enhanced magnetic resonance angiography (CEMRA) when DUS demonstrates 50% or higher stenosis; Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy U-King-Im J M, Hollingworth W, Trivedi R A, Cross J J, Higgins N J, Graves M J, Gutnikov S, Kirkpatrick P J, Warburton E A, Antoun

More information

ACE Standards. for Carotid Artery Stenting Accreditation. Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care

ACE Standards. for Carotid Artery Stenting Accreditation. Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care 2015 ACE Standards for Carotid Artery Stenting Accreditation Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care 1100 17th St. NW, Ste 330 Washington D.C. 20036 1 Accreditation

More information

Abstract. Introduction A SIMULATION STUDY OF ESTIMATORS FOR RATES OF CHANGES IN LONGITUDINAL STUDIES WITH ATTRITION

Abstract. Introduction A SIMULATION STUDY OF ESTIMATORS FOR RATES OF CHANGES IN LONGITUDINAL STUDIES WITH ATTRITION A SIMULATION STUDY OF ESTIMATORS FOR RATES OF CHANGES IN LONGITUDINAL STUDIES WITH ATTRITION Fong Wang, Genentech Inc. Mary Lange, Immunex Corp. Abstract Many longitudinal studies and clinical trials are

More information

Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL

Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL Carotid Technologies and Protection Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL Disclosure Statement

More information

CAS as first line of treatment in the future

CAS as first line of treatment in the future Azienda Ospedaliera Universitaria Senese CHIRURGIA VASCOLARE Chief:Prof. Carlo Setacci CAS as first line of treatment in the future Prof. Carlo Setacci Chief of Vascular Surgery University of Siena - Italy

More information

Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate?

Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate? Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University

More information

What to do with missing data in clinical registry analysis?

What to do with missing data in clinical registry analysis? Melbourne 2011; Registry Special Interest Group What to do with missing data in clinical registry analysis? Rory Wolfe Acknowledgements: James Carpenter, Gerard O Reilly Department of Epidemiology & Preventive

More information

Randomised Trials of Carotid Interventions Will the Changing Technology of Membrane Mesh Stents Shape The Future?

Randomised Trials of Carotid Interventions Will the Changing Technology of Membrane Mesh Stents Shape The Future? Randomised Trials of Carotid Interventions Will the Changing Technology of Membrane Mesh Stents Shape The Future? Dr Sumaira Macdonald MBChB (Comm.), FRCP, FRCR, PhD, EBIR Vascular Interventional Radiologist

More information

Assessment of the procedural etiology of stroke resulting from carotid artery stenting

Assessment of the procedural etiology of stroke resulting from carotid artery stenting Assessment of the procedural etiology of stroke resulting from carotid artery stenting 1. Study Purpose and Rationale: A. Background Stroke is the 3 rd leading cause of death in the United States and carries

More information

Carotid Endarterectomy for Symptomatic Complete Occlusion of the Internal Carotid Artery

Carotid Endarterectomy for Symptomatic Complete Occlusion of the Internal Carotid Artery 2011 65 4 239 245 Carotid Endarterectomy for Symptomatic Complete Occlusion of the Internal Carotid Artery a* a b a a a b 240 65 4 2011 241 9 1 60 10 2 62 17 3 67 2 4 64 7 5 69 5 6 71 1 7 55 13 8 73 1

More information

Health-Related Quality of Life After Carotid Stenting Versus Carotid Endarterectomy

Health-Related Quality of Life After Carotid Stenting Versus Carotid Endarterectomy Journal of the American College of Cardiology Vol. 58, No. 15, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.054

More information

FRANK J. VEITH MAC TH MUNICH VASCULAR CONF

FRANK J. VEITH MAC TH MUNICH VASCULAR CONF UPDATE ON THE NORTH AMERICAN RCTs CREST 2 & ACST 1: WILL CAS SURVIVE AS AN ALTERNATIVE TO BMT OR CEA? FRANK J. VEITH 6 TH MUNICH VASCULAR CONF MAC - 2016 MUNICH DECEMBER 1, 2016 I HAVE NO FINANCIAL CONFLICTS

More information